[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intensive-care-medicine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intensive-care-medicine":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,46,77,118,156,185,215,249,270,295,322,351,381,405],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100561856","intelligent-lung-support-in-the-intensive-care-unit-100561856",false,"NCT06595602","Intelligent Lung Support in the Intensive Care Unit","Intelligent Lung Support in the Intensive Care Unit (IntelliLung): An Observational, Prospective, Multicentre Study","IntelliLung","Inclusion Criteria:\n\n1. Male and female patients, age ⪰18 years\n2. Written informed consent\n3. Invasively mechanically ventilated patients expected to be intubated for more than 24 hours.\n\nExclusion Criteria:\n\n1. Expected to die within ≤48 hours\n2. Participation in an interventional mechanical ventilation trial\n3. Mechanical Ventilation with a closed-loop ventilation mode\n4. Persons dependent on the sponsor and\u002For investigator\n5. Subjects who are currently imprisoned or otherwise in confinement ordered by law or other official authorities","ALL","18 Years",{"count":20,"type":21},530,"ESTIMATED","OBSERVATIONAL","The aim of this observational study is to test the IntelliLung decision support system based on artificial intelligence. This system is intended to help to set the ventilator. The study includes patients with and without ARDS (acute respiratory distress syndrome) who are receiving invasive mechanical ventilation, as well as patients with additional extracorporeal lung support. The study will be conducted in several centers.\n\nThe main question of the study:\n\nHow well do the mechanical ventilation settings of healthcare staff match the recommendations of the IntelliLung system?",[25,26],"Mechanical Ventilation","Intensive Care Medicine",[28,29,30,31,32],"Invasive mechanical ventilation","Intensive care medicine","critical care medicine","artificial intelligence","decision support","RECRUITING","2026-06-30",{"date":36,"type":37},"2026-07-02","ACTUAL",{"date":39,"type":37},"2025-05-25",{"date":41,"type":21},"2027-12",{"name":43,"class":44},"Technische Universität Dresden","OTHER",5,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":57,"conditions":58,"keywords":64,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100612143","factor-associated-with-mortality-in-the-icu-100612143","NCT07249749","Factor Associated With Mortality in the ICU","Factors Associated With Mortality in the Intensive Care Unit From the Orinoco Region. An Observational Trial","ICUMortal","Inclusion Criteria:\n\n* All adult patients older than 18 admitted to the intensive care unit during the study period.\n\nExclusion Criteria:\n\n* Patients admitted for intermediate care (low therapeutic intervention with a TISS \\[Therapeutic Intervention Scoring System\\] - 28 score below 20 points). Patients derived to other institutions.","100 Years",{"count":56,"type":21},1000,"ICU mortality indicates the severity of disease, healthcare quality, and the efficacy of interventions. The severity scores are tools to predict the risk of mortality in the ICU, and the APACHE II score is frequently used for this purpose. However, studies validating the score in Colombia are limited. There is uncertainty about the precision and discrimination capacity of the APACHE II score in a population that varies from the original, with varying diseases, and in a different timeline. The investigators determined to evaluate: 1. Evaluate the rate of mortality in the ICU by type of disease and type of admission. 2. The factors associated with mortality. 3. Validate the performance of the APACHE II score as a predictor of mortality.",[59,60,26,61,62,63],"Critically Ill","Intensive Care (ICU)","Mortality","Mortality Prediction","Mortality in Intensive Care Units",[59,65,61,66],"Intensive Care Unit","Colombia","2026-05-25",{"date":69,"type":37},"2026-05-27",{"date":71,"type":37},"2026-01-10",{"date":73,"type":21},"2028-12-21",{"name":75,"class":44},"Hospital Departamental de Villavicencio",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":97,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":117},"100556548","phase-3-recommend-platform-trial-100556548","NCT06526533","RECOMMEND Platform Trial","Generating New Evidence to Reduce Major Complications to Improve the Safety and Efficacy of ECMO in Severe Cardiac and Respiratory Failure (RECOMMEND)","RECOMMEND","PLATFORM INCLUSION CRITERIA:\n\n* Patients receiving ECMO\n* Patients enrolled in the EXCEL Registry - NCT03793257\n\nPLATFORM EXCLUSION CRITERIA:\n\n* Treating clinician regards death as imminent and inevitable\n* Treating clinician determines it is not in the patient's best interests\n\nRBC TRANSFUSION DOMAIN INCLUSION CRITERIA:\n\n• Aged 18 years or older\n\nRBC TRANSFUSION DOMAIN EXCLUSION CRITERIA:\n\n* Contraindication to RBC transfusion (including known patient preference)\n* Limitations of care put in place either through patient wishes or the treating medical teams.\n* Participant has already received ECMO \\>12 hours. The start of ECMO is defined as the time of initiation of extracorporeal blood flow unless ECMO was initiated during a surgical intervention in which case the start of ECMO is defined as the arrival time into the initial ICU (post-surgery)\n* The treating physician anticipates that ECMO treatment will cease before the end of tomorrow\n* The treating physician deems the study is not in the patient's best interest\n* The treating physician has concern regarding patient ability to tolerate restrictive or liberal transfusion trigger thresholds\n* Actively listed for a solid organ transplant and has not yet received one\n* Suspected or confirmed to be pregnant\n* Previous ECMO treatment during the same hospital admission",true,{"count":87,"type":21},600,"INTERVENTIONAL",[90],"PHASE3","The goal of this platform trial is to determine the efficacy, safety and cost-effectiveness of various interventions in patients with acute cardiorespiratory failure requiring extracorporeal membrane oxygenation (ECMO)\n\nThe main question the platform trial aims to address is to determine the effect of a range of interventions on survival, organ support and resource utilisation to day 28 for hospitalised patients receiving ECMO.\n\nResearchers will compare various interventions within multiple platform trial domains to see if the interventions have effects on survival, organ support and resource utilisation for the patient cohort.\n\nParticipants will be enrolled in accordance with the platform trial's domain structure to answer the research questions.",[93,94,26,95,96],"Extracorporeal Membrane Oxygenation Complication","ARDS (Acute Respiratory Distress Syndrome)","Cardiac Arrest (CA)","Critical Illness",[98,99,100,101,102,103,104,105,106,107],"ECMO","ICU","Platform Trial","Australia","Cardiac","Respiratory","VA","VV","eCPR","Adaptive","2026-05-11",{"date":110,"type":37},"2026-05-13",{"date":112,"type":37},"2026-03-23",{"date":114,"type":21},"2029-06",{"name":116,"class":44},"Australian and New Zealand Intensive Care Research Centre",3,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":128,"conditions":129,"keywords":137,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":76},"100595479","improving-sedation-practice-in-critically-ill-adult-patients-using-a-co-designed-sedation-protocol-100595479","NCT07032987","Improving Sedation Practice in Critically Ill Adult Patients Using a Co-designed Sedation Protocol","Optimising Analgosedation in Extracorporeal Membrane Oxygenation (ECMO) Using a Co-designed Analgosedation Protocol","ECMO-SED","Stage 1 (multi-centre observational study):\n\nInclusion Criteria:\n\n1. Aged 18 years and older.\n2. Receiving continuous IV infusions of analgosedation (opioids, benzodiazepines, and\u002For propofol).\n3. Receiving ECMO for moderate to severe respiratory failure (PaO2\u002FFiO2 (P\u002FF) ratio \\\u003C20 kilopascals (kPa)) for ≤ 7 days during the week of recruitment.\n4. Non-ECMO ICU patients (control group): must satisfy inclusion criteria 1 and 2, and have received mechanical ventilation for moderate to severe respiratory failure (P\u002FF ratio \\\u003C 20kPa) for at least 48 hours OR mechanical ventilation for cardiovascular disorder (out of hospital cardiac arrest, following cardiothoracic or transplant surgery or percutaneous coronary intervention or acute heart failure).\n\nExclusion Criteria:\n\n1. Anticipated length of ICU stay in recruiting centre for less than 24 hours.\n2. Withdrawal of life-sustaining treatment in the next 24 hours.\n\nStage 2 (mixed methods study):\n\nInclusion Criteria:\n\n1. Healthcare professionals working at one of two ECMO centres (St Thomas' Hospital and Royal Brompton Hospital (part of Guy's and St Thomas' NHS Foundation Trust).\n2. ECMO survivors (patients admitted to ICU and survived ECMO organ support) who have returned home, and recovered.\n3. Family members of ECMO survivors, whose relative is no longer hospitalised.\n\nExclusion Criteria:\n\n1. ECMO survivors currently receiving treatment in hospital.\n2. ECMO survivors with severe cognitive issues (issues with short-term memory and thinking).\n3. ECMO survivors who cannot communicate in English.\n4. Non-ECMO survivors and family members.",{"count":127,"type":21},120,"Sedation (painkillers and sedative drugs) treats pain, reduces suffering, and helps patients in the intensive care unit (ICU) receiving extracorporeal membrane oxygenation (ECMO) remain comfortable. ECMO is a life support machine that provides oxygen and removes waste gases (carbon dioxide) in very sick patients with severe heart or lung failure. About 300-400 patients per year receive ECMO in the UK. These patients are younger and generally more healthy compared to other critically ill patients. However patients that survive ECMO have long-term health problems. These include anxiety, memory problems, withdrawal from medicines, and mobility issues. These problems issues could all be related to the type and amount of sedation given.\n\nA sedation protocol is a way of guiding healthcare professionals how much sedation is given to patients in ICU. Too much sedation can cause confusion, hallucinations, excessive sleepiness, and longer time in hospital. Too little sedation can cause pain, distress, and also a longer time in hospital. Using a sedation protocol in non-ECMO patients has been shown to reduce these complications.\n\nHowever, there are no protocols for giving sedation to ECMO patients in research papers. The investigators know healthcare staff find it difficult to manage sedation, and higher amounts of sedation is given to ECMO patients.\n\nAims:\n\n* To describe current sedation use in ECMO patients in the UK and compare to non-ECMO critically ill patients.\n* To develop a sedation protocol for ECMO patients with input from patients, their family, and staff.\n\nDesign\u002Fmethods:\n\nStudy 1:\n\nThe investigators will study how sedation is used in adult ECMO patients and compare with non-ECMO but critically ill patients in the UK. The investigators will collect information on drug doses and pain and sedation scores. The investigators will also ask ECMO centres if they use a sedation protocol to adjust sedation doses. This information will be helpful for the design of the protocol in study 2.\n\nStudy 2:\n\nThe investigators will design a sedation protocol with input from patients, family, and staff. The investigators will organise meetings to share experiences and agree on what to include in the protocol that is considered acceptable and safe. The investigators will then assess if the protocol is safe and acceptable with staff outside the co-design group.\n\nPatient and public involvement\u002Fengagement:\n\nThe investigators received feedback from patients and family members which helped to design this proposal, the lay summary and what to measure in a trial. Patients and family members will continue to help with development of the sedation and trial protocol. They will advise how the investigators should review study findings, and support sharing of results to the public.\n\nImpact\u002Fdissemination:\n\nThe investigators will share findings through social media, patient charities, research papers and conferences.",[26,130,131,132,133,134,135,136],"Respiratory Distress Syndrome (RDS)","Sedation and Analgesia","ExtraCorporeal Membrane Oxygenation (ECMO)","Sedation for Mechanical Ventilation","Cardiogenic Shock","Opioid Analgesia","Analgesia",[138,139,140,141,142,143,98,99,65,144,145,146],"extracorporeal membrane oxygenation","sedation","opioid","sedatives","analgosedation","mechanical ventilation","Critical Care","sedation protocol","analgesia","2026-05-05",{"date":149,"type":37},"2026-05-08",{"date":151,"type":37},"2025-11-24",{"date":153,"type":21},"2027-08-31",{"name":155,"class":44},"Guy's and St Thomas' NHS Foundation Trust",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":85,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":182,"locationsCount":184},"100581663","functional-incremental-stepping-in-place-test-f-ist-validation-100581663","NCT06853236","Functional Incremental Stepping in Place Test (F-IST) Validation","A Cardiorespiratory Fitness Test for Acute Illness: Validity, Reliability, and Clinical Utility of Functional Incremental Stepping-in-Place Test","F-IST","Inclusion Criteria:\n\n-Currently able to walk with or without a walking aid, such as a cane or walker or rollator\n\nExclusion Criteria:\n\nPregnancy\n\nspecifically related to cardiopulmonary testing\n\n* A recent significant change in resting ECG\n* Unstable angina\n* Uncontrolled cardiac dysrhythmias causing symptoms or hemodynamic compromise\n* Symptomatic severe aortic stenosis\n* Uncontrolled symptomatic heart failure\n* Acute pulmonary embolus or pulmonary infarction\n* Acute myocarditis or pericarditis\n* Suspected or known dissecting aneurysm\n* Acute systemic infection accompanied by fever, body aches, or swollen lymph glands\n* Left Main Coronary Stenosis\n* Moderate stenotic valvular heart disease\n* Electrolyte abnormalities\n* Severe arterial hypertension (\\>200 systolic, \\>110 diastolic) at rest\n* Tachydysrhythmia or bradydysrhythmia\n* Hypertrophic cardiomyopathy and other forms of outflow tract obstruction\n* Neuromuscular, musculoskeletal, or rheumatic disorders that are exacerbated by exercise\n* High degree AV block\n* Ventricular aneurysm\n* Uncontrolled metabolic disease (diabetes, thyrotoxicosis, or myxedema)\n* Chronic infectious disease (hepatitis, AIDS, mono)\n* Mental or physical impairment leading to inability to exercise adequately",{"count":165,"type":21},60,"The purpose of this multi-site prospective study is to assess validity of a new step test called Functional-Incremental Stepping-in-place- Test (F-IST) compared to gold-standard cardiopulmonary exercise testing (CPET) and to physical function and health perception, respectively. The investigators will also assess test-retest reliability of the F-IST. The investigators hypothesize that the F-IST will have high validity and test-retest reliability to be used in field testing environments such as the ICU.",[26,168],"Acute Care Medical",[170,171,172,173,174,175],"Cardio respiratory fitness","incremental step test","validity","reliability","physical function","graded exercise testing","2026-03-16",{"date":178,"type":37},"2026-03-17",{"date":180,"type":37},"2024-07-02",{"date":36,"type":21},{"name":183,"class":44},"Kirby Mayer",2,{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":88,"phases":195,"briefSummary":196,"conditions":197,"keywords":204,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":214},"100579076","phase-3-prophylaxis-against-early-ventilator-associated-infections-in-acute-brain-injury-100579076","NCT06819592","PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury","PRophylaxis Against Early VENTilator-associated Infections to Reduce Mortality in Mechanically Ventilated Intensive Care Unit (ICU) Patients With Acute Brain Injuries: a Phase 3 Randomised, Double Blind, Parallel Group, Placebo-controlled Two-side Superiority Trial","PREVENT-NEURO","Inclusion Criteria:\n\n1. ≥ 18 years of age\n2. Receiving invasive mechanical ventilation\n3. The requirement for mechanical ventilation is because of an acute brain injury due to intracranial haemorrhage, ischaemic stroke, cerebral venous sinus thrombosis, subarachnoid haemorrhage, suspected hypoxic ischaemic encephalopathy post cardiac arrest, or traumatic brain injury.\n4. Admitted to an ICU or is anticipated to be admitted to an ICU\n\nExclusion Criteria:\n\n1. Endotracheal intubation was more than 12 hours ago\n2. Hospital admission was more than 72 hours ago\n3. Anticipated inability to deliver trial intervention within 90 minutes of randomisation\n4. Documented use of antibiotic therapy in the week prior to hospitalisation\n5. Currently receiving antibiotic therapy, or intention to prescribe antibiotic therapy, excluding cephazolin for peri-operative prophylaxis\n6. Any contraindication to receiving ceftriaxone\n7. Known or suspected pregnancy\n8. Death within 90 days is deemed inevitable due to the current illness or intercurrent medical conditions\n9. Previously enrolled in the PREVENT-NEURO trial.",{"count":194,"type":21},3300,[90],"This research is about whether treatment with a commonly used antibiotic can prevent infections in airway and lungs and improves the chance of surviving, if it is given soon after patients commence mechanical ventilation when they have been admitted to hospital with an acute severe brain injury.\n\nAn acute severe brain injury can occur as a result of a stroke, a traumatic injury or due to lack of oxygen to the brain that happens as a result of a cardiac arrest.\n\nPatients who are unconscious after an acute severe brain injury often need assistance to breath adequately, and this assistance is given by a breathing tube, connected to a mechanical ventilator. This treatment is an emergency medical treatment. The breathing tube is inserted into the patients' airway by either their mouth or neck. For patients who need assistance with their breathing from a mechanical ventilator, infections in the airways and lungs, known as pneumonia, are a common complication. Everyone naturally has bacteria in their mouth, esophagus and stomach. Clinicians think that during the process of inserting the breathing tube, small amounts of these bacteria can be introduced into the airways and lung when people are unconscious following an acute severe brain injury, or during the process of placing the breathing tube into the airways. These bacteria are now in a place they aren't meant to be and can cause an infections in the airways and lungs known as pneumonia.\n\nThe purpose of this research is to see if giving one dose of a common antibiotic can prevent patients developing pneumonia, which is associated with having a breathing tube inserted and being on a ventilator, improving the chance of recovery following the acute severe brain injury and ultimately improving the chance of surviving.\n\nWhen patients have a known infection, current guidelines are to treat them with antibiotics. Antibiotics work to kill the bacteria causing the infection. When a patient has an infection in their lungs, they often need to stay on the mechanical ventilator for longer. While current practice is to give patients with a proven infection in their airways and lungs (pneumonia) antibiotics, it is unknown if giving an antibiotic to patients to prevent these infections before they show signs of pneumonia may lead to better outcomes.",[198,199,200,201,202,203,26],"All-cause Mortality","Quality of Life","Disability, Intellectual","Neurological Disorder","Acute Brain Injury","Ventilation, Mechanical",[202,25],"2026-02-16",{"date":207,"type":37},"2026-02-19",{"date":209,"type":37},"2025-10-30",{"date":211,"type":21},"2029-12",{"name":213,"class":44},"The George Institute",9,{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":88,"phases":225,"briefSummary":227,"conditions":228,"keywords":233,"overallStatus":240,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":245,"leadSponsor":247,"locationsCount":76},"100621237","end-of-life-care-in-mechanically-ventilated-patients-impact-of-a-comprehensive-palliative-care-protocol-in-the-intensive-care-setting-100621237","NCT07368010","End-of-life Care in Mechanically Ventilated Patients: Impact of a Comprehensive Palliative Care Protocol in the Intensive Care Setting","End-of-life Care in Mechanically Ventilated Patients: Impact of a Comprehensive Training to Palliative Care in the Intensive Care Setting. A Multicenter Cluster Randomised Trial","ARREVE-3","Inclusion Criteria:\n\n* Patient:\n\n  * Age ≥ 18 years\n  * ICU admission for more than 48 hours\n  * Receiving invasive mechanical ventilation\n  * A documented decision to withdraw life-sustaining therapies, made through a multidisciplinary collegial process and communicated to the designated surrogate decision-maker, family, or relatives\n  * At least one visit from a relative prior to the decision to withdraw life-sustaining therapies\n  * Provision of informed consent for study participation, or, if the patient lacks decision-making capacity, consent obtained from a relative or legally authorized representative\n* Relative:\n\n  * Age ≥ 18 years\n  * Has received at least one medical update regarding the patient's clinical status from an ICU physician prior to the decision to withdraw life-sustaining therapies\n  * Has provided informed consent for study participation\n\nExclusion Criteria:\n\n* Patient:\n\n  * Presence of a tracheostomy\n  * Brain death or involvement in an organ donation procedure\n  * Absence of any visit from a relative\n  * Subject to legal guardianship or other legal protection measures\n  * Incarcerated patient\n  * Participation in another interventional research study focused on end-of-life care\n  * Pregnant or breastfeeding woman\n* Relative:\n\n  * Inability to understand or speak French\n  * Subject to legal guardianship or other legal protection measures",{"count":224,"type":21},720,[226],"NA","The ARREVE-3 trial will evaluate whether a structured palliative care protocol can improve end-of-life management for mechanically ventilated ICU patients in whom a decision to withdraw life-sustaining therapies has been made. This cluster-randomized controlled trial compares protocol-based care with usual practice across participating centers. The intervention includes comprehensive guidance on symptom management, sedation, nursing care, withdrawal procedures, and family support, supported by standardized staff training. The primary endpoint is adherence to recommended end-of-life practices, while secondary outcomes assess patient comfort, communication with relatives, and the impact on families and healthcare professionals",[229,230,26,231,232],"Palliative Care","Withdrawal of Life Support","Sedation","Dying Process",[234,235,143,236,237,238,139,239],"End of life","intensive care medicine","organ support","withdrawal","life support","palliative care","NOT_YET_RECRUITING","2026-01-20",{"date":243,"type":37},"2026-01-26",{"date":71,"type":21},{"date":246,"type":21},"2029-01-10",{"name":248,"class":44},"Nantes University Hospital",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":88,"phases":258,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":76},"100587059","voicelove-an-app-based-communication-tool-designed-to-address-delirium-and-improve-family-engagement-and-patientfamily-satisfaction-in-critically-ill-patients-communicate-100587059","NCT06923462","VoiceLove: An App-Based COMMunication Tool Designed to Address DeliriUm and Improve Family ENgagement and PatIent\u002FFamily SatisfaCtion in CriticAlly Ill PaTiEnts (COMMUNICATE)","COMMUNICATE","Inclusion Criteria\n\nOnly patients who meet inclusion criteria, have no exclusion criteria, and consent for participation will advance to the Interventional Trial phase (i.e., the randomization phase) of the study. Patients will be eligible for inclusion in the Pre-Randomization Phase of the study (i.e., presented for study consent) if they are:\n\n1. Adult patient ≥18 years old\n2. Admitted to medical or coronary ICU\n3. Intubated on mechanical ventilation with expected intubation of \\> 24 hours\n\nExclusion Criteria\n\nPatients will be excluded (i.e., not consented) for any of the following reasons:\n\n1. Inability to obtain informed consent\n\n   * Attending physician refusal\n   * Patient and\u002For surrogate refusal\n   * Patient unable to consent and no surrogate available\n2. Acute or chronic neurologic deficit precluding CAM-ICU assessments\n3. Inability to understand English\n4. Current enrollment in a study that does not allow co-enrollment\n5. Prisoners\n6. Expected death or comfort measures within 24 hours of enrollment or lack of commitment to intervention by family or the medical team (e.g., likely to withdraw life support measures within 24 hours of enrollment).\n7. Bilateral Deafness",{"count":257,"type":21},100,[226],"VoiceLove is a phone application allowing family and patients to share information in a secure platform. This project will compare the VoiceLove app to usual care to learn about whether VoiceLove improves patient-family communication, family engagement, and ICU delirium.",[96,26],"2025-08-26",{"date":263,"type":37},"2025-08-27",{"date":265,"type":37},"2025-08-06",{"date":267,"type":21},"2028-03-15",{"name":269,"class":44},"Vanderbilt University Medical Center",{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":279,"conditions":280,"keywords":283,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":291,"leadSponsor":293,"locationsCount":76},"100588988","prognosis-of-cirrhotic-patients-admitted-to-the-general-intensive-care-unit-between-2014-and-2024-a-regional-retrospective-multicentre-cohort-study-100588988","NCT06948565","Prognosis of Cirrhotic Patients Admitted to the General Intensive Care Unit Between 2014 and 2024: a Regional Retrospective Multicentre Cohort Study","REACIRRHOSE","Inclusion Criteria:\n\nPatients with cirrhosis over 18 years of age (cirrhosis either histologically proven or diagnosed by hepatologists according to clinical, biological and ultrasound criteria) admitted to intensive care between January 2014 and December 2024.\n\nExclusion Criteria:\n\nNone",{"count":278,"type":21},500,"Ten years after our team's publication, practices have changed considerably in the management of severe cirrhotic patients. This study will analyse these practices in primary care hospitals and in a tertiary centre, and assess the impact of these changes on the prognosis of these patients.\n\nThe following hypotheses will be tested:\n\n* Improvement in intensive care and overall prognosis compared with data from the literature prior to 2014\n* Improved access to liver transplantation compared with the literature prior to 2014\n* Improvement in intensive care unit practices (for example: application of recommendations published by learned societies concerning the intensive care unit management of patients with cirrhosis, access to comfort care, degree of clinical severity on admission to the intensive care unit, etc.).\n* Centre' effect: variability in the phenotype of patients admitted to intensive care depending on the technical facilities available and whether or not the hospital centre has access to TH.",[281,26,282],"Cirrhosis","Acute on Chronic Liver Failure(ACLF)",[284,285,99,286],"prognosis","cirrhosis","ACLF","2025-08-08",{"date":289,"type":37},"2025-08-11",{"date":287,"type":37},{"date":292,"type":21},"2026-12",{"name":294,"class":44},"Centre Hospitalier Universitaire de Besancon",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":88,"phases":304,"briefSummary":305,"conditions":306,"keywords":310,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":76},"100579103","effectiveness-of-platform-based-lateralization-therapy-in-reducing-interface-pressure-between-the-patient-and-the-support-surface-100579103","NCT06819943","Effectiveness of Platform-Based Lateralization Therapy in Reducing Interface Pressure Between The Patient And The Support Surface","PREVENT-ICU","Inclusion Criteria\n\n* Adult and elderly patients, aged 18 years or older;\n* Patients under controlled or assisted mechanical ventilation, not yet eligible for weaning.\n\nExclusion Criteria\n\n* Requirement of norepinephrine \\> 0.3 mcg\u002Fkg\u002Fmin or mean arterial pressure \\\u003C 60 mmHg, despite the use of vasopressor agents;\n* Cardiac arrhythmias or bleeding leading to hemodynamic instability;\n* Neurological diseases or symptoms;\n* Spinal cord injury, such as paraplegia;\n* Cardiac pacemaker dependence;\n* Contraindications to hypercapnia, such as intracranial hypertension or acute coronary syndrome;\n* Air leakage from chest drains, presence of pneumothorax or undrained subcutaneous emphysema;\n* Presence of pre-existing pressure injuries in bony prominences (sacral, occipital, scapular, or calcaneal) at admission;\n* Medical refusal to include the patient in the study.",{"count":303,"type":21},25,[226],"Pressure injury (PI) is characterized as damage to the skin and\u002For underlying tissues resulting from sustained pressure or a combination of pressure and shear forces between the patient and the support surface. Prolonged pressure is a well-established risk factor in the development of PIs. Frequent repositioning and routine patient care have been recognized for decades as integral components of PI prevention and treatment protocols.\n\nThe duration of interface pressure is as critical as its magnitude. When interface pressure exceeds the mean capillary blood pressure, blood flow can be compromised, leading to ischemia in affected areas, which may progress to necrosis if sustained over time. Furthermore, it is widely accepted in the literature that tissue becomes at risk when interface pressure exceeds 30 to 32 mmHg.\n\nIn this context, continuous lateral rotation therapy (CLRT) offers a potential alternative for managing critically ill patients. CLRT involves continuous mechanical rotation of the patient in the lateral plane. However, its effects on skin integrity remain poorly understood. Despite the rationale behind and widespread recommendation of repositioning, the lack of robust evaluations on how repositioning impacts interface pressure creates uncertainty, underscoring the need for high-quality trials to assess different strategies for implementation.\n\nAlthough lateralization is a pragmatic strategy for preventing pressure injuries, its use in critically ill patients requires an integrated assessment of respiratory, hemodynamic, and gastroesophageal effects. Therefore, this study proposes an innovative approach by evaluating, for the first time, the effectiveness of automated postural change with simultaneous monitoring of tissue integrity, pulmonary function, cardiovascular stability, and gastroesophageal protection. The aim is to optimize pressure injury prevention, improve pulmonary mechanics, ensure hemodynamic stability, and preserve gastroesophageal safety in critically ill patients.",[307,308,26,309],"Respiratory Insufficiency","Pressure Injury","ARDS",[311,312],"Continuous Lateral Rotation Therapy","Rotation Therapy","2025-06-17",{"date":315,"type":37},"2025-06-22",{"date":317,"type":37},"2024-06-01",{"date":319,"type":21},"2027-10",{"name":321,"class":44},"University of Sao Paulo General Hospital",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":88,"phases":332,"briefSummary":334,"conditions":335,"keywords":338,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":347,"leadSponsor":349,"locationsCount":76},"100589759","phase-4-pulsed-electromagnetic-field-therapy-or-pneumatic-compression-vte-prophylaxis-100589759","NCT06958588","Pulsed Electromagnetic Field Therapy or Pneumatic Compression VTE Prophylaxis","Pulsed Electromagnetic Field Therapy (PEMF) Compared to Conventional Mechanical Prophylaxis for Venous Thromboembolism Prophylaxis in Patients in the Intensive Care Unit (ICU)","SOPHIE","Inclusion Criteria:\n\n1. Patients \\> 18 years old in ICU\n2. PADUA score\\> 4 (medical patients) and\u002For Caprini score\\> 3 (surgical patients)\n3. Contraindication to pharmacological prophylaxis or indication to combined (pharmacological and mechanical VTE prophylaxis)\n\nExclusion Criteria:\n\n1. Patients \\\u003C 18 years old in ICU\n2. Unable to use mechanical prophylaxis due to trauma, burns, fracture, or problems in inferior members that prevent the use of mechanical prophylaxis\n3. Life expectations less than 24 hours",{"count":331,"type":21},50,[333],"PHASE4","Venous thromboembolism (VTE) is frequent in patients in the intensive care unit (ICU). Pharmacologic prophylaxis is sometimes contraindicated, and mechanical prophylaxis is used. The primary objective of the study is to compare Pulsed Electromagnetic Field Therapy (PEMF) with conventional mechanical prophylaxis for the prevention of VTE in patients in the ICU.",[336,26,337],"Venous Thromboembolism (VTE)","Venous Thromboembolism",[339,340,341,99,342],"venous thromboembolism","Mechanical prophylaxis","Pulsed Electromagnetic Field Therapy (PEMF)","intensive care unit","2025-04-25",{"date":345,"type":37},"2025-05-06",{"date":39,"type":21},{"date":348,"type":21},"2026-03-20",{"name":350,"class":44},"Science Valley Research Institute",{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":359,"targetDuration":361,"studyType":22,"phases":4,"briefSummary":362,"conditions":363,"keywords":366,"overallStatus":240,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":76},"100586214","to-evaluate-transport-safety-between-different-scanning-methods-for-patients-in-the-intensive-care-unit-icu-100586214","NCT06912464","To Evaluate Transport Safety Between Different Scanning Methods for Patients in the Intensive Care Unit (ICU)","Comparative Safety Analysis: PET vs. CT Scans During Intensive Care Admission","CASA","Inclusion Criteria:\n\n* Patients receiving PET\u002FCT during ICU admission (any indication)\n* Patients undergoing CT Thorax\u002FAbdomen (matched cohort)\n\nExclusion Criteria:\n\n* CT-scan for any acute indication (acute danger to vital parameters).\n* CT-Cerebrum\n* Registrion in the dutch Objection to medical research registry.",{"count":360,"type":21},208,"2 Days","The goal of this study is to assess how safe it is for critically ill patients in the Intensive Care Unit (ICU) to undergo a PET scan. A PET scan is a type of medical imaging used to help determine why a patient is sick. It is similar to a CT scan but involves a small amount of radioactivity to highlight areas of concern in the body.\n\nFor a PET scan, patients need to be transported from the ICU to the scanning room, which can be risky because ICU patients are often very fragile. After a patient gets the PET scan injection, their body gives off a small amount of radiation for a short time. Because of this, doctors and nurses have to keep some distance to protect themselves. This means they keep an eye out for the patient from a bit further away than normal. This makes the procedure slightly riskier, especially for very sick patients.\n\nThis study aims to answer the question:\n\nIs getting a PET scan riskier for ICU patients than a regular CT scan?\n\nAll patients in this study will continue to receive their usual critical care. Researchers will closely monitor the scanning process to evaluate its safety.\n\nPET scans are already widely used to detect cancer, but new advancements may allow us to use them more often to diagnose infections. Before this can become routine practice, we need to ensure that PET scanning is just as safe as other commonly used imaging techniques. This study will assess all ICU patients undergoing a PET scan-regardless of the reason for the scan-to determine how safe the procedure is in critically ill individuals.",[364,365,26],"Transportation of Patients","PET \u002F CT",[367,26,99,368,369,370,371],"Intrahospital transport (IHT)","PET","PET\u002FCT","Safety","CT","2025-03-31",{"date":374,"type":37},"2025-04-04",{"date":376,"type":21},"2025-04-01",{"date":378,"type":21},"2027-04-01",{"name":380,"class":44},"University Medical Center Groningen",{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":88,"phases":391,"briefSummary":392,"conditions":393,"keywords":4,"overallStatus":240,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":404},"100582309","optimization-of-morphinomimetic-administration-intraoperatively-evaluation-of-the-impact-of-the-nol-index-on-the-occurrence-of-postoperative-adverse-events-related-to-morphinomimetics-100582309","NCT06861634","Optimization of Morphinomimetic Administration Intraoperatively: Evaluation of the Impact of the NOL Index on the Occurrence of Postoperative Adverse Events Related to Morphinomimetics","Optimization of Morphinomimetic Administration Intraoperatively: Evaluation of the Impact of the NOL Index on the Occurrence of Postoperative Adverse Events Related to Morphinomimetics: A Randomized Controlled Trial","NOL-Impact","Inclusion Criteria:\n\n* Male or female\n* Subject aged ≥ 18 years\n* Affiliated with a social security scheme\n* Having given written informed consent to participate study\n* Admitted for major surgery expected to last more than 2 hours\n* Under general anesthesia with tracheal intubation\n* For a planned hospital stay of at least 48 hours\n* Participant's ability to understand the nature and objectives of the study to comply with study requirements.\n\nExclusion Criteria:\n\n* Contraindication to one of the drugs used for anesthesia\n* Urgent surgery\n* Intracranial surgery\n* Transplant surgery\n* Cardiac surgery\n* Surgery with scheduled local anesthesia\n* Patient requiring postoperative intubation\n* Neuromuscular disease\n* Patient chronically using morphinomimetics\n* Chronic pain patient\n* Patients with a history of sleep apnea\n* Conditions likely to interfere with photoplethysmograph signal acquisition or skin conductance (excessive or tremors of the extremities, skin lesions or burns)\n* Patients wearing false nails and\u002For nail polish\n* Contraindication to the use of the PMD 200 ™ medical device (including cardiovascular resuscitation and cardioversion\u002Fdefibrillation);\n* Patient with an implanted pacemaker or defibrillator\n* Treatment with β-blockers\n* Preoperative cardiac arrhythmia\n* Pregnant or breast-feeding women. A β-HCG test will be systematically performed prior to inclusion of non-menopausal women menopausal women\n* Patients under legal protection (safeguard of justice, curatorship guardianship) or deprived of liberty\n* Participation in other interventional research involving an experimental drug or medical device.",{"count":390,"type":21},332,[226],"Reducing the quantity of morphinomimetics during the operative period reduces the prevalence and intensity of adverse effects.\n\nHowever, morphinomimetics are indispensable during surgery, as they limit the autonomic nervous system's deleterious reactions to nociception. The administration of these drugs in intravenous boluses during surgery is usually guided by their duration of action and by variations in heart rate and blood pressure. Other events, such as hypovolemia or extreme surgical position, may stimulate the autonomic nervous system outside of nociception. These events, along with routine drug administration, can lead to undue consumption of morphinomimetics.\n\nThe Nol index, a multiparametric monitor of nociception, is based on analysis of variations in plethysmography waveform, heart rate and skin conductance. It has been demonstrated that the use of this type of monitor can reduce intraoperative consumption of morphinomimetics and optimize their administration. Does intraoperative morphinomimetic administration optimized by the NOL index have an impact on the occurrence of dose-dependent adverse effects?",[394,26],"Anesthesia","2025-03-05",{"date":397,"type":37},"2025-03-06",{"date":399,"type":21},"2025-03",{"date":401,"type":21},"2028-04",{"name":403,"class":44},"University Hospital, Tours",6,{"id":406,"slug":407,"hasResults":11,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":414,"conditions":415,"keywords":416,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":184},"100574227","evaluating-the-use-of-artificial-intelligence-to-improve-family-conversations-for-intensive-care-patients-and-their-families-100574227","NCT06756542","Evaluating the Use of Artificial Intelligence to Improve Family Conversations for Intensive Care Patients and Their Families","Utilizing Large Language Models to Augment Family Conversations in the Intensive Care Unit","Inclusion Criteria:\n\n* Informed-consent is signed by all participating family members during the conversation.\n* Informed-consent is signed by the ICU healthcare professionals.\n* The patient of the family must be admitted to the adult ICU.\n* All participating family members must be 18 years or older.\n* The family conversation must be in Dutch.\n\nExclusion Criteria:\n\n* Trained to interpret medical jargon and\u002For intensive care terminology specifically\n* Difficulty reading and\u002For writing in the Dutch language",{"count":413,"type":21},40,"This study looks at how artificial intelligence (AI), like generative pre-trained transformer (GPT-4), can help doctors in the intensive care unit (ICU) save time and improve communication with families. Right now, doctors spend a lot of time writing notes after family conversations, which takes time away from patient care. The investigators are testing whether AI can create accurate and easy-to-understand summaries of these conversations, making it quicker for doctors to document and clearer for families to understand. ICU doctors and adult family members of patients will take part in this study, with their full consent. The goal is to see if this new technology can make life easier for doctors while helping families better understand medical information.",[26,144],[417,31,418,419,420],"intensive care","large language models","administration reduction","patient satisfaction","2025-02-24",{"date":423,"type":37},"2025-02-25",{"date":425,"type":37},"2025-01-14",{"date":427,"type":21},"2025-12",{"name":429,"class":44},"Davy van de Sande"]